PubMed Health⌕ Search

PubMed · 15260576

Modeling diffusion in miscible polymer blend films.

Abstract

Recent experiments designed to probe polymer transport in the bulk and in the vicinity of surfaces have examined the interdiffusion of multilayer sandwiches of isotopically labeled polymers. The measured time dependent concentration profiles normal to the surface are typically fit to Fick's law, with a single fitting parameter, the mutual binary diffusion coefficient (MBDC). The resulting MBDCs are found to vary over a broad range of film thicknesses and time, with the time dependence being viewed as a unique signature of the reptation mechanism of long chain motion, and the thickness dependence being attributed to the slowing down of chain dynamics near surfaces. Since the experiments are conducted at finite concentration, the MBDC, which is a product of the bare mobility and the concentration derivative of the chemical potential, could be dominated by the time and thickness dependence of this second term (which is ignored in Fick's law). To quantify this conjecture we consider the more rigorous Cahn formulation of the diffusion problem in terms of chemical potential gradients. We use square gradient theory to evaluate chemical potentials, and fit the resulting time dependent concentration profiles to the analytical solution of Fick's law. By thus mimicking the experimental analysis we find that the apparent MBDCs vary with time as t(-1/2) at short times, in good agreement with existing experiments. We show that this time dependence reflects the system's desire to minimize concentration gradients, a fact ignored in Fick's law. Since these arguments make no reference to the mechanism of chain motion, we argue that the time dependence of MBDC derived from interdiffusion experiments does not provide unequivocal support for the reptation mechanism of long chain transport. The MBDC values, which also vary with the degree of confinement, are predicted to increase with decreasing thickness for model parameters corresponding to experimental systems. In contrast, since the experimental fits yield an opposite trend, we suggest that the bare mobility of the chains decreases strongly with decreasing thickness. These findings strongly support the idea that the chains are "pinned" irreversibly to the surfaces, in good agreement with other, independent experiments.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ananth Indrakanti, Narayan Ramesh, J Larry Duda, Sanat K Kumar. 2004-07-01. Modeling diffusion in miscible polymer blend films.. https://doi.org/10.1063/1.1760078

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗